Peginterferon plus NAs for stable hepatitis B cirrhosis
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests a combination of two drugs—peginterferon alfa-2b and a nucleoside analogue (like tenofovir or entecavir)—to see if they work better together for people with stable, compensated cirrhosis from hepatitis B. It aims to improve liver health and reduce the risk of complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have cirrhosis of the liver caused by hepatitis B that is stable (not causing serious complications like belly swelling or confusion).
- You do not have other liver diseases like fatty liver, alcoholic liver, or autoimmune hepatitis.
- You are not pregnant, breastfeeding, or planning to get pregnant soon, and you agree to use birth control during the study.
- You are generally healthy aside from the hepatitis B cirrhosis (no serious heart, lung, thyroid, or nerve conditions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether additional peginterferon treatment can further reduce the virus in the liver for people with chronic hepatitis B who have already reached a clinical cure. You would need to have two liver biopsies to check the virus levels.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
This study tests whether adding a pegylated interferon (a medicine that boosts your immune system) to your current hepatitis B treatment can help lower your hepatitis B virus levels even more. It is for people with chronic hepatitis B who have not had interferon recently and do not have fatty liver disease.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This study tests whether a long-acting interferon medication can help people with chronic hepatitis B who have already received interferon treatment clear the hepatitis B virus more completely. It's designed for patients whose virus levels dropped significantly during their first treatment but haven't gone away.
Hear when a new HBV-related Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.